← All Sponsors
SPONSOR

ORIC Pharmaceuticals

Total Trials
1
Recruiting
1
Phases
Phase 1, Phase 2
Conditions studied: Solid Tumors
NCT05315700 Phase 1, Phase 2
Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Solid Tumors
United States, Australia, Canada View Trial →